Exelixis, Inc. (EXEL)

Over the past six months, Exelixis's stock (EXEL) has seen an increase of 22.23%. Key events impacting the stock include strong Q3 2025 financial results with an additional stock repurchase program, the FDA acceptance of the New Drug Application for zanzalintinib, and strong Q4 and fiscal year 2025 financial results. There has been significant insider selling over the past three months. Analyst sentiment remains mixed, with a consensus "Hold" rating.

Demand for Exelixis, Inc.'s products, particularly CABOMETYX, does not appear to be significantly affected by seasonality. The company has stated that its gross-to-net (GTN) is stable and "unaffected by seasonality due to the small manufacturer designation."

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company's major products are derived from cabozantinib, including CABOMETYX® tablets approved for advanced renal cell carcinoma (RCC), previously treated hepatocellular carcinoma (HCC), and previously treated, radioactive iodine-refractory differentiated thyroid cancer, and COMETRIQ® capsules approved for progressive, metastatic medullary thyroid cancer (MTC). The company also offers COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone). Exelixis is advancing a pipeline of investigational therapies, including zanzalintinib, which is in pivotal trials for various cancers.

Exelixis, Inc. is primarily a U.S. oncology-focused biopharma company, with its headquarters in Alameda, California. The company's products are commercialized in the United States, and it collaborates with partners for sales of cabozantinib outside the U.S. MINNEBRO is approved for the treatment of hypertension in Japan.

Exelixis's brand reputation is tied to its strong financial performance and advancements in its oncology pipeline. Positive events contributing to its reputation include strong financial results, pipeline advancement, and share repurchase programs. However, insider selling, a decline in its gross-to-net percentage in Q4 2025, and flat Cabometyx sales have introduced caution.

The ownership structure of Exelixis, Inc. is heavily dominated by institutional investors, who collectively held approximately 85.27% of the company's stock as of July 2025. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Farallon Capital Management Llc. Insiders own approximately 4.03% of the company's stock.